Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Change in Receivables (2019 - 2025)

Benitec Biopharma's Change in Receivables history spans 6 years, with the latest figure at $226000.0 for Q1 2025.

  • For Q1 2025, Change in Receivables changed N/A year-over-year to $226000.0; the TTM value through Mar 2025 reached $176000.0, changed N/A, while the annual FY2024 figure was $176000.0, 252.0% up from the prior year.
  • Change in Receivables for Q1 2025 was $226000.0 at Benitec Biopharma, up from -$226000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $226000.0 in Q1 2025 and bottomed at -$226000.0 in Q3 2024.
  • The 4-year median for Change in Receivables is $7000.0 (2021), against an average of $25000.0.
  • The largest YoY upside for Change in Receivables was 757.14% in 2022 against a maximum downside of 771.43% in 2022.
  • A 4-year view of Change in Receivables shows it stood at -$7000.0 in 2021, then skyrocketed by 757.14% to $46000.0 in 2022, then crashed by 591.3% to -$226000.0 in 2024, then skyrocketed by 200.0% to $226000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Change in Receivables are $226000.0 (Q1 2025), -$226000.0 (Q3 2024), and $176000.0 (Q2 2024).